Earnings Summary on United Therapeutics
United Therapeutics (NASDAQ:UTHR), a biotechnology company focused on therapies for rare and serious conditions such as pulmonary arterial hypertension, released its second-quarter results on July 30, 2025. The company posted record GAAP revenue and earnings, continuing its streak of double-digit GAAP revenue growth, but missed Wall Street forecasts. GAAP revenue climbed to $798.6 million, but came in $3.3 million below consensus expectations. GAAP earnings per share rose to $6.41, up 10% year over year, yet missed estimates by $0.88. The quarter featured robust product growth, especially in the Tyvaso franchise, but higher operating and one-time costs weighed on profits. Overall, the quarter reflected strong operational momentum but underscored some emerging risks around costs and the company’s reliance on a single product family.
Source: Analyst estimates for the quarter provided by FactSet.
United Therapeutics develops and markets specialty medicines for rare cardiovascular and cancer conditions. Its main focus is on treatments for pulmonary arterial hypertension, a type of high blood pressure affecting the lungs and heart. The company is also a pioneer in organ manufacturing and regenerative medicine, with ongoing clinical programs in 3D bioprinting and xenotransplantation.
Source Fool.com
